Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,064.43 +46.04 (+0.92%) Dow
38,241.50 +338.21 (+0.89%) Nasdaq
15,832.81 +227.32 (+1.46%) Bitcoin USD
59,302.55 +899.41 (+1.54%) CMC Crypto 200
1,272.55 +1.81 (+0.14%)
argenx SE (ARGX)
| Previous close | 383.34 |
| Open | 387.38 |
| Bid | 390.08 x 100 |
| Ask | 390.51 x 100 |
| Day's range | 384.29 - 391.43 |
| 52-week range | 327.73 - 550.76 |
| Volume | |
| Avg. volume | 271,350 |
| Market cap | 23.2B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.14 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 478.76 |
GlobeNewswireargenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/in
- GlobeNewswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that data from its Phase 3 ADHERE tri
Insider MonkeyHere’s Why argenx SE (ARGX) Pulled Back 23% in Q4
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy underperformed the Russell Midcap Growth Index and returned 13.66% (gross) and 13.44% (net) while the index return was -14.55%. In addition, please check […]
